FDA-cleared profile

Contour ProtégéAI+

Mim Software, Inc. · Radiological images; modality varies or is not specified in FDA list · FDA-cleared (510(k))

Authorized purpose: Contour ProtégéAI+ processes CT and MR DICOM images and generates contours for quantitative analysis, adaptive therapy, image registration, transfer to radiotherapy planning, and archiving subject to qualified review and editing.

Clinical role
Radiotherapy image processing, structure contouring, registration, quantitative analysis, or planning-workflow support.
Images and patients
Radiological images; modality varies or is not specified in FDA list · Multi-region
Key limitation
Keep in mind: Anatomy, modality, structure set, registration, treatment site, software version, and required independent checks are release-specific. Contour ProtégéAI+ processes CT and MR DICOM images and generates contours for quantitative analysis, adaptive therapy, image registration, transfer to radiotherapy planning, and archiving subject to qualified review and editing.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Contour ProtégéAI+ processes CT and MR DICOM images and generates contours for quantitative analysis, adaptive therapy, image registration, transfer to radiotherapy planning, and archiving subject to qualified review and editing.
  • Which images or clinical context are in scope?Modality: Radiological images; modality varies or is not specified in FDA list Anatomy or clinical context: Multi-region Input: Supported CT or MR DICOM studies, contours, treatment-planning metadata, and release-specific workflow inputs.
  • Who uses it?Intended users: Qualified radiation oncologists, dosimetrists, physicists, therapists, and trained imaging professionals.
  • What does the software produce?Output: Contours, registrations, measurements, processed images, or planning-workflow objects for qualified review and approval.
  • What is its most important limitation?Key limitation: Anatomy, modality, structure set, registration, treatment site, software version, and required independent checks are release-specific. Contour ProtégéAI+ processes CT and MR DICOM images and generates contours for quantitative analysis, adaptive therapy, image registration, transfer to radiotherapy planning, and archiving subject to qualified review and editing.

Clinical takeaway. Clinical role: Contour ProtégéAI+ processes CT and MR DICOM images and generates contours for quantitative analysis, adaptive therapy, image registration, transfer to radiotherapy planning, and archiving subject to qualified review and editing.

Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports verification and validation in which the subject device was evaluated on test subjects from a pool of 189 images gathered from 7 institutions, using non-inferiority testing against atlases from the MIM Maestro reference device, Dice and MDA versus original ground-truth contours, and user beta testing of time savings. Each individual feature met the acceptance criteria; the CT Male Pelvis model showed a performance reduction on female patients. Results are as reported in the FDA submission, not independent validation.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Contour ProtégéAI+ processes CT and MR DICOM images and generates contours for quantitative analysis, adaptive therapy, image registration, transfer to radiotherapy planning, and archiving subject to qualified review and editing.
  • Exact FDA submission
  • Checked 2026-09-04
Workflow role
Radiotherapy image processing, structure contouring, registration, quantitative analysis, or planning-workflow support.
  • Exact FDA submission
  • Checked 2026-09-04
Required input
Supported CT or MR DICOM studies, contours, treatment-planning metadata, and release-specific workflow inputs.
  • Exact FDA submission
  • Checked 2026-09-04
Output and clinician action
Contours, registrations, measurements, processed images, or planning-workflow objects for qualified review and approval.
  • Exact FDA submission
  • Checked 2026-09-04
Care setting
Radiation oncology planning, contouring, or image-management environments using compatible CT, MR, or DICOM workflows.
  • Exact FDA submission
  • Checked 2026-09-04
Intended users
Qualified radiation oncologists, dosimetrists, physicists, therapists, and trained imaging professionals.
  • Exact FDA submission
  • Checked 2026-09-04
Limitations
Anatomy, modality, structure set, registration, treatment site, software version, and required independent checks are release-specific. Contour ProtégéAI+ processes CT and MR DICOM images and generates contours for quantitative analysis, adaptive therapy, image registration, transfer to radiotherapy planning, and archiving subject to qualified review and editing.
  • Exact FDA submission
  • Checked 2026-09-04
Evidence summary
The exact FDA document reports verification and validation in which the subject device was evaluated on test subjects from a pool of 189 images gathered from 7 institutions, using non-inferiority testing against atlases from the MIM Maestro reference device, Dice and MDA versus original ground-truth contours, and user beta testing of time savings. Each individual feature met the acceptance criteria; the CT Male Pelvis model showed a performance reduction on female patients. Results are as reported in the FDA submission, not independent validation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Non-inferiority testing was used to compare the Contour ProtégéAI+ subject device to Atlases created from the MIM Maestro (K071964) reference device." … "The Contour ProtégéAI+ subject device was evaluated on the test subjects from a pool of 189 images gathered from 7 institutions.". Read from the exact FDA decision document on 2026-11-14.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The exact FDA document reports verification and validation in which the subject device was evaluated on test subjects from a pool of 189 images gathered from 7 institutions, using non-inferiority testing against atlases from the MIM Maestro reference device, Dice and MDA versus original ground-truth contours, and user beta testing of time savings. Each individual feature met the acceptance criteria; the CT Male Pelvis model showed a performance reduction on female patients. Results are as reported in the FDA submission, not independent validation.
  • FDA source
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Non-inferiority testing was used to compare the Contour ProtégéAI+ subject device to Atlases created from the MIM Maestro (K071964) reference device." … "The Contour ProtégéAI+ subject device was evaluated on the test subjects from a pool of 189 images gathered from 7 institutions.". Read from the exact FDA decision document on 2026-11-14.

Reported sensitivity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No exact submission and version-linked sensitivity endpoint is published in this dossier; do not substitute a product-family or candidate-study value.

Reported specificity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No exact submission and version-linked specificity endpoint is published in this dossier; do not substitute a product-family or candidate-study value.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

FDA submission-specific verification and validation evidence for K253270

  • DesignRegulatory verification, validation, and labeling evidence reviewed for exact FDA submission K253270.
  • PopulationThe labeled population and test materials for exact submission K253270; a general clinical study population is not established here.
  • Scopeexact submission
  • Tested versionContour ProtégéAI+ (K253270)
  • IndependenceSponsor or vendor study

K253270

FDA regulatory evidence is submission-specific but is not independent clinical performance evidence.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Supported CT or MR DICOM studies, contours, treatment-planning metadata, and release-specific workflow inputs.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-04 · FDA decision summary for K253270 - Contour ProtégéAI+

  2. Routing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. Exact submission evidence and the current vendor family material do not establish the exact site's DICOM, worklist, PACS/RIS, identity, routing, display, or fallback behavior.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-04 ·

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. Exact deployment topology, hosting, network boundaries, update mechanism, and local operational requirements are not established for this submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-04 ·

  4. Returned objects

    Source context, not route validation: Contours, registrations, measurements, processed images, or planning-workflow objects for qualified review and approval.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-04 · FDA decision summary for K253270 - Contour ProtégéAI+

  5. Viewer/worklist/report

    Unresolved route: Contours, registrations, measurements, processed images, or planning-workflow objects for qualified review and approval.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-04 · FDA decision summary for K253270 - Contour ProtégéAI+

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Security
MIM Software's security page states SOC 2 Type 2 status, penetration testing and continuous vulnerability scanning of released products, coordinated vulnerability disclosure and a public security advisories page. Vendor-wide.
  • Vendor-wide
  • Checked 2026-10-25

Vendor statement, not an attestation; exact-release scope is not established.

Workflow role

Radiotherapy image processing, structure contouring, registration, quantitative analysis, or planning-workflow support.

exact submission · checked 2026-09-04

This is a submission-anchored intended-use summary, not a local acceptance result.

Input

Supported CT or MR DICOM studies, contours, treatment-planning metadata, and release-specific workflow inputs.

exact submission · checked 2026-09-04

Exact supported inputs and protocol limits must be confirmed from the complete labeling.

Output

Contours, registrations, measurements, processed images, or planning-workflow objects for qualified review and approval.

exact submission · checked 2026-09-04

Output review, editing, and downstream use remain release- and site-specific.

Vendor family context

Current vendor material is product-family context for K253270 only; exact release, enabled options, deployment, and local interoperability require confirmation.

product family · checked 2026-09-04

Vendor material is not exact-release evidence unless that linkage is separately proven.

Site validation status

Exact local interfaces, deployment topology, security controls, downtime behavior, and support obligations remain unestablished.

exact submission · checked 2026-09-04

Obtain organization-specific implementation evidence before procurement or clinical use.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K253270
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Radiological images; modality varies or is not specified in FDA list
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Anatomy
Multi-region
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2026-03-27
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-19Last searched
28Fields reviewed
14Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, vendor documentation, fda decision summary, vendor product page, implementation documentation, reimbursement policy, peer reviewed literature, clinical trial registry, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No public exact-release price, license fee, subscription, contract, or implementation cost was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not applicable - checked 2026-09-04 - Not applicable

    CMS index context was checked, but no product-specific coverage or reimbursement determination is inferred.

  • Deployment: Not publicly available - checked 2026-09-04 - Exact FDA submission

    Exact deployment topology, hosting, network boundaries, update mechanism, and local operational requirements are not established for this submission.

  • Integration: Not publicly available - checked 2026-09-04 - Exact FDA submission

    Exact submission evidence and the current vendor family material do not establish the exact site's DICOM, worklist, PACS/RIS, identity, routing, display, or fallback behavior.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-10-27 - Exact FDA submission

    Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.

  • Monitoring: Not verified - checked 2026-10-27 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

9 sources - 3 history items

Source ledger

  1. FDA decision summary for K253270 - Contour ProtégéAI+

    U.S. Food and Drug Administration - Published 2026-03-27 - Accessed 2026-09-04

    Scope: regulatoryIdentity, productIdentity, indication, modality, anatomy, workflowRole, input, output, limitations, evidenceSummary

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. Radiation Oncology Model

    Centers for Medicare & Medicaid Services - Accessed 2026-09-02

    Scope: reimbursement, radiationTherapyPaymentContext

  8. MIM Software contouring family context

    MIM Software - Accessed 2026-09-04

    Scope: productFamilyContext, workflowRole, implementationCapabilities

  9. MIM Software Security

    MIM Software - Accessed 2026-10-25

    Scope: security

Research history

  1. K253270 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K254207

AiORTA - Plan v2.0

ViTAA Medical Solutions, Inc.

Authorized purpose: AiORTA - Plan v2.0 is image-processing and analysis software for the labeled radiotherapy-planning workflow; exact modalities, structures, inputs, outputs, and user-review requirements remain submission-specific.

Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Multi-region
Decision
2026-03-30
FDA-cleared K252539

Tempus Pixel

Arterys, Inc.

Authorized purpose: Multimodality DICOM image management, quantitative analysis, optional cardiovascular MR mapping and flow analysis, and therapy-response lesion tracking for trained clinicians.

Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Multi-region
Decision
2025-09-03
FDA-cleared K243647

Synapse PACS (7.5)

FUJIFILM Healthcare Americas Corporation

Authorized purpose: Synapse PACS version 7.5 provides primary processing and presentation of DICOM and supported non-DICOM images with measurement, segmentation, fusion, volume rendering, reporting, integrated 3D, two-point VOI, and AI-assisted bone removal.

Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Multi-region
Decision
2025-06-30
FDA-cleared K243933

Ceevra Reveal 3+

Ceevra, Inc.

Authorized purpose: CT and MR 3D segmentation, measurements and interactive models for adult preoperative and intraoperative surgical planning; not primary diagnosis.

Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Multi-region
Decision
2025-03-04

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history